Corpus Intelligence IC Memo — ADVENTIST HEALTH TULARE 2026-04-26 09:37 UTC
IC Memo — ADVENTIST HEALTH TULARE
Investment Committee Memorandum | CA | 73 beds | Grade D | EBITDA uplift $3.7M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

ADVENTIST HEALTH TULARE

CCN 050784 | TULARE, CA | 73 beds | April 26, 2026
EBITDA BridgeData Room
D
Investability

1. Target Overview & Investment Thesis

ADVENTIST HEALTH TULARE is a 73-bed under-performing / distressed in TULARE, CA with $49.6M in net patient revenue and a -75.8% operating margin. The hospital serves a payer mix of 27.4% Medicare, 2.5% Medicaid, and 70.1% commercial.

Thesis: Turnaround. Our ML models identify $3.7M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -75.8% to -68.4% (+736bps).

Net Revenue HCRIS$49.6M
Current EBITDA COMPUTED$-37.6M
Operating Margin COMPUTED-75.8%
Occupancy HCRIS33.9%
Revenue / Bed COMPUTED$680K
Net-to-Gross HCRIS15.4%
Distress Probability ML50.5%

2. Market Context & Competitive Position

414
CA Hospitals
-4.9%
State Median Margin
142
Comparable Hospitals

CA has 414 Medicare-certified hospitals with a median operating margin of -4.9%. The target's margin of -75.8% places it below the state median. Among 142 size-comparable peers (36-146 beds), the median margin is -4.7%. The target's below-peer margin suggests operational improvement opportunity.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (36-146), prioritizing same-state peers. 142 hospitals in the comp set.

HospitalStateBedsRevenueMargin
ADVENTIST HEALTH TULARE (Target)CA73$49.6M-75.8%
CONTRA COSTA REGIONAL MEDICAL CA124$595.0M-29.2%
RANCHO LOS AMIGOS NATL.REHAB.CCA83$512.6M41.9%
USC NORRIS CANCER HOSPITALCA60$468.7M19.1%
KFH - ANTIOCHCA144$445.4M8.1%
KFH - VACAVILLECA144$415.3M7.1%
EDEN MEDICAL CENTERCA126$389.8M2.7%
KFH - REDWOOD CITYCA140$379.7M-4.5%
SUTTER SANTA ROSA REGIONAL HOSCA124$374.4M-0.2%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $3.7M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$1.0M+210bp18mo
Cost to Collect4.5%2.5%$992K+200bp12mo
Denial Rate Reduction12.0%6.5%$982K+198bp12mo
A/R Days Reduction5200.0%3800.0%$604K+122bp9mo
Clean Claim Rate88.0%96.0%$32K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$1.0M
Cost to Collect
$992K
Denial Rate Reduction
$982K
A/R Days Reduction
$604K
Clean Claim Rate
$32K
Total EBITDA Uplift$3.7M
Current EBITDA$-37.6M
+ RCM Uplift+$3.7M
Pro Forma EBITDA$-33.9M
Current Margin-75.8%
Pro Forma Margin-68.4%
WC Released (1x)$1.9M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-57.8M$-211.5M0.00x-100.0%
Base (11x exit)10.0x11.0x$-57.8M$-251.4M0.00x-100.0%
Bull Case9.0x11.0x$-52.1M$-258.1M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-52.1M$-297.0M0.00x-100.0%
Bear Case11.0x10.0x$-63.6M$-210.9M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-63.6M$-252.7M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion
MediumLow occupancyAt 33.9%, fixed costs are spread over fewer patient days. Mitigant: volume growth is an additional upside lever not modeled in base case
HighElevated distress probabilityModel estimates 50.5% probability of financial distress. Mitigant: distressed entry pricing (7-9x) compensates for risk
LowLow net-to-gross ratioLarge contractual allowances suggest pricing discipline issues. Mitigant: payer renegotiation is an additional upside lever

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 142 hospitals with 36-146 beds
  • Same-state prioritization (n=143)
  • Comp margins: P25=-21.2% / P50=-4.7% / P75=3.5%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.